Copenhagen: Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said Friday its chief executive was stepping down from his role.
"A search for Lars Fruergaard Jorgensen's successor is ongoing, and an announcement will be made in due course," the company said in a statement, adding that the decision had been a "mutual agreement with the Novo Nordisk board ... in light of the recent market challenges Novo Nordisk has been facing and the development of the company's share price since mid-2024".
